Purisys
Purisys is a pharmaceutical CDMO in Athens, Georgia that provides drug substance manufacturing, including controlled substances and early-phase development services, to global pharmaceutical and biotech clients as part of Siegfried Holding AG's integrated CDMO platform.
- Company typePrivate
- Founded2019
- HeadquartersAthens, Greece
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Purisys does
Purisys, LLC is a pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Athens, Georgia, that produces drug substances for pharmaceutical clients, with a specific specialization in controlled substance manufacturing and early-phase development services. The company operates a manufacturing site in Athens as part of the broader Noramco Group, which collectively maintains three manufacturing facilities across Wilmington (Delaware), Athens (Georgia), and Tasmania (Australia), employing approximately 400 people in total. Purisys's product offering is centered on small-molecule API manufacturing, including scheduled controlled substances requiring DEA-level regulatory compliance, supplied under contract manufacturing agreements to global pharmaceutical and biotech clients such as Ensysce Biosciences.
Purisys operates a B2B enterprise sales model, engaging pharmaceutical company procurement and R&D teams directly through contract manufacturing relationships rather than through transactional or self-serve channels. Revenue is generated via professional services-style contract manufacturing agreements, with pricing quote-based and not publicly disclosed. The company's horizontal segmentation targets pharmaceutical and biotech companies requiring specialized manufacturing capacity for drug substances, particularly those with controlled substance or abuse-deterrent formulations requiring FDA-aligned manufacturing approaches.
Historically, Purisys was a privately held portfolio company of SK Capital Partners within the Noramco Group. In January 2026, SK Capital agreed to sell Purisys alongside Noramco and Extractas Biosciences to Swiss-listed Siegfried Holding AG in a transaction valued below 10x EV/EBITDA. The sale closed in May 2026 as part of Siegfried's EVOLVE+ strategy to expand US-based drug substance manufacturing capacity, integrating Purisys into Siegfried's global small-molecule CDMO platform. Post-acquisition, Purisys operates as a subsidiary within Siegfried, with James Mish serving as CEO and President.
Purisys firmographics
Firmographics- Name
- Purisys
- Legal name
- Purisys, LLC
- Website
- https://purisys.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Purisys is a pharmaceutical CDMO in Athens, Georgia that provides drug substance manufacturing, including controlled substances and early-phase development services, to global pharmaceutical and biotech clients as part of Siegfried Holding AG's integrated CDMO platform.
- Ownership category
- akta.pro rank
Purisys industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Purisys is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Offices1 record
Markets served
Purisys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Infrastructure, Personnel, Technology or R&D
Revenue model
- Contract Manufacturing Services: Purisys generates revenue through contract development and manufacturing services for pharmaceutical companies, producing drug substances including controlled substances. The business operates as a CDMO providing manufacturing capacity for early-phase development and commercial production.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Purisys product offering
Product offeringCore offering
Purisys is a pharmaceutical contract development and manufacturing organization (CDMO) providing drug substance manufacturing services, including specialized controlled substance production, at its Athens, Georgia facility. The company supports pharmaceutical clients with small-molecule API manufacturing from early-phase development through commercial production, operating within the Noramco Group and now Siegfried Holding AG's global CDMO network.
Product overview
Purisys is a pharmaceutical contract development and manufacturing organization (CDMO) that operates as part of the Noramco Group, providing drug substance manufacturing services. The company operates a manufacturing site in Athens, Georgia and offers early-phase development capabilities combined with controlled substance manufacturing expertise. Purisys was recently sold by SK Capital Partners to Siegfried Holding AG along with Noramco and Extractas Biosciences. The company's services support pharmaceutical manufacturing for controlled substances and early-stage drug development.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmaceutical Drug Substance Manufacturing Contract development and manufacturing organization (CDMO) services providing pharmaceutical drug substance manufacturing, including controlled substance production, for pharmaceutical companies and biotech firms requiring FDA-compliant manufacturing capacity.
- Early-Phase Development Services Early-phase pharmaceutical development services combined with controlled substance manufacturing expertise, supporting pharmaceutical clients from development through commercial production within the Noramco Group portfolio.
Companies that use Purisys
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Purisys technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Purisys partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- GalepharcorePurisys partnered with Galephar as manufacturing partners for Ensysce Biosciences' PF614 product, advancing phase 3 trial manufacturing activities.
- Ensysce BiosciencescorePurisys, LLC (a subsidiary of Noramco, LLC) serves as a manufacturing partner for Ensysce Biosciences' PF614 abuse-resistant opioid product. The partnership supports FDA-aligned manufacturing approach and commercial production of the micro-particle delivery technology. FDA provided written guidance aligning with manufacturing plans for PF614, enabling the company to proceed towards commercial production.
Scale indicators4 records
Recent moves6 records
Expansion highlights3 records
Purisys competitors and assessment
Company assessmentDirect peers
- Cambrex: Small-molecule API and finished dosage CDMO serving global pharmaceutical clients. Highly comparable in offering (small-molecule drug substance development and manufacturing) and customer segment.
- Carbogen Amcis: API and drug substance CDMO with strong capabilities in highly potent and complex small molecules, including controlled substances. Comparable in regulatory complexity and target pharma customers.
- Extractas Bioscience: Tasmania-based natural extract and API manufacturer co-acquired with Purisys by Siegfried. Comparable as a specialty API manufacturer operating within the same integrated platform.
- Halo Pharmaceuticals: North American CDMO retained by SK Capital Partners after divesting Purisys. Closely comparable in scale, customer type, and CDMO service offering (finished-dose and drug product).
- Siegfried Holding AG: Swiss-listed CDMO and now parent company of Purisys. Operates a global network of small-molecule API and drug product manufacturing sites and is the most direct comparator in scale, service portfolio, and target customers.
- Noramco: Sister company within the Noramco Group and co-acquired by Siegfried. Specializes in controlled-substance API manufacturing, making it the closest peer in terms of chemistry, regulatory scope, and customer base.
Broad incumbents
- Recipharm: European-headquartered CDMO offering small-molecule API and drug product services to global pharma clients. Comparable in service scope and target customers as a broad incumbent.
- Johnson Matthey (Health): Large, diversified specialty chemicals and pharma services business offering API and catalyst manufacturing. Comparable as a broad incumbent in small-molecule CDMO services with deeper resources.
- Aenova: European CDMO with strong small-molecule API and finished dose form capabilities serving pharma clients. Overlaps with Purisys in target customers and core service offering.
- Catalent: Large global CDMO providing a broad portfolio including small-molecule drug substance and drug product services. Competes for the same enterprise pharma CDMO contracts as Purisys, though at materially greater scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Purisys social profiles
Digital presencePurisys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Purisys leadership team
Management profileNumber of profiles
Profiles1 record
Purisys funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Purisys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Purisys
What does Purisys do?
Purisys is a pharmaceutical contract development and manufacturing organization (CDMO) providing drug substance manufacturing services, including specialized controlled substance production, at its Athens, Georgia facility. The company supports pharmaceutical clients with small-molecule API manufacturing from early-phase development through commercial production, operating within the Noramco Group and now Siegfried Holding AG's global CDMO network.
Is Purisys a public or private company?
Purisys is a private company. It is classified as corporate owned and is currently acquired.
When was Purisys founded?
Purisys was founded in 2019. It employs 51 to 100 people.
Where is Purisys based?
Purisys is headquartered in Athens, Greece, in the Europe region.
How does Purisys make money?
One revenue line is on record: contract Manufacturing Services.
Who are Purisys's main competitors?
Direct peers on record are Cambrex, Carbogen Amcis, Extractas Bioscience, Halo Pharmaceuticals, Siegfried Holding AG and Noramco. Broad incumbents are Recipharm, Johnson Matthey (Health), Aenova and Catalent.
Does Purisys have an API?
No public API is recorded for Purisys.
What industry is Purisys in?
Purisys's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 32541 and its SIC code is 2834.